Patent US4283393A successfully refreshed from Google Patents.
US4283393A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical application of interferon inducers
Assignee: Merck and Co Inc
•
Filing: 1979-03-13
•
Granted: 1981-08-11
•
Expires: 1999-03-13
Abstract
Abstract Virus infections of eye, skin and mucous membrane tissue are effectively treated by controlled release topical application of interferon inducers.
Inventors
- 👤 Arthur K. Field
- 👤 Richard J. Harwood
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 14:05
CPC Classifications
C; C07; C07H; C07H21/00; A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/30; A61K47/32; A61K47/36; A61K47/38; A61K9/00; A61K9/0012; A61K9/0014; A61K9/0048
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
75 words
An improved method of treating virus infections of skin, eye and mucous membrane tissue susceptible to treatment with interferon by topically applying a therapeutically effective antiviral amount of an interferon inducer selected from the group consisting of synthetic double-stranded RNA, a natural double-stranded RNA, and a nonpolynucleotide, the improvement consisting of incorporating said interferon inducer and a water soluble polymer selected from the group consisting of cellulose ethers, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinylpolymer and polyethylene glycol.
Claim 2
Dependent Claim
75 words
An improved method of treating virus infections of skin, eye and mucous membrane tissue susceptible to treatment with interferon by topically applying a therapeutically effective antiviral amount of an interferon inducer selected from the group consisting of synthetic double-stranded RNA, a natural double-stranded RNA, and a nonpolynucleotide, the improvement consisting of incorporating said interferon inducer and a water soluble polymer selected from the group consisting of cellulose ethers, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinylpolymer and polyethylene glycol.
Claim 3
Dependent Claim
82 words
An improved composition for the treatment of virus infections of skin, eye and mucous membrane tissue susceptible to treatment with interferon comprising a therapeutically effective antiviral amount of an interferon inducer selected from the group consisting of synthetic double-stranded RNA, natural double-stranded RNA, and a nonpolynucleotide, the improvement consisting of incorporating said interferon inducer in a homogeneous mixture of said interferon inducer and a water soluble polymer selected from the group consisting of cellulose ethers, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinylpolymer and polyethylene glycol.
Claim 4
Dependent Claim
82 words
An improved composition for the treatment of virus infections of skin, eye and mucous membrane tissue susceptible to treatment with interferon comprising a therapeutically effective antiviral amount of an interferon inducer selected from the group consisting of synthetic double-stranded RNA, natural double-stranded RNA, and a nonpolynucleotide, the improvement consisting of incorporating said interferon inducer in a homogeneous mixture of said interferon inducer and a water soluble polymer selected from the group consisting of cellulose ethers, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinylpolymer and polyethylene glycol.
Claim 5
Dependent Claim
12 words
The method of claim 1 wherein the interferon inducer is poly I:C.
Claim 6
Dependent Claim
15 words
The method of claim 1 or 3 wherein the tissue is that of the eye.
Claim 7
Dependent Claim
13 words
The formulation of claim 2 wherein the water-soluble polymer is a cellulose ether.
Claim 8
Dependent Claim
11 words
The formulation of claim 2 wherein the cellulose ether is hydroxypropylcellulose.
Claim 9
Dependent Claim
15 words
The formulation of claim 2, 5 or 6 wherein the interferon inducer is poly I:C.
Claim 10
Dependent Claim
21 words
The formulation of claim 2, 5 or 6 adapted for use on the eye, wherein the interferon inducer is poly I:C.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-08-10 | 1985-02-09 | 1985-08-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-08-10 | 1989-02-09 | 1989-08-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-08-10 | 1993-02-09 | 1993-08-11 | $7700.00 | Window Closed / Lapsed |